// App-Quantinova.ai

2581 : Phase 1 study assessing dovitinib (TKI258) on the pharmacokinetics of caffeine, diclofenac, omeprazole, and midazolam in patients with advanced solid tumors.

Researchers

Presenter

  • Ding Wang

Principal Investigators

  • Raymond P. Perez

  • Massimiliano Quadrigli

  • Jeffrey W. Scott

  • Fadi S. Braiteh

  • Rebecca Anne Moss

  • Shu Yang

  • Xiaoming Cui

Medical Centers

  • Novartis AG, Basel, Switzerland

  • Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJComprehensive Cancer Centers of Nevada, Las Vegas, NVNovartis Pharmaceuticals Corp, East Hanover, NJ

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • University of Kansas, Division of Hematology/Oncology, Fairway, KS

  • Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, MI

Locations

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Diclofenac

  • Omeprazole

  • Midazolam

  • Dovitinib

  • Caffeine

Outcome

  • Positive

Study Design

  • drug-drug interaction

  • pharmacokinetics

Phase

  • I

Study Id's

  • NCT01596647

Sponsors

  • Novartis

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved